Recursion Pharmaceuticals financials
$4.03+8.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $74.7M | $58.8M | $44.6M | $39.8M | $10.2M |
| Gross profit | $3.7M | $13.6M | $2.0M | -$8.4M | $10.2M |
| Gross margin | 5.0% | 23.1% | 4.5% | −21.2% | 100.0% |
| Operating income | -$648.1M | -$479.0M | -$350.1M | -$245.7M | -$182.8M |
| Net income | -$644.8M | -$463.7M | -$328.1M | -$239.5M | -$186.5M |
| Net margin | −863.4% | −788.0% | −736.0% | −601.0% | −1832.2% |
| Diluted EPS | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 |
| EBITDA | -$564.4M | -$442.5M | -$325.7M | -$234.0M | -$174.4M |
| Operating cash flow | -$371.8M | -$359.2M | -$287.8M | -$83.5M | -$158.6M |
| Free cash flow | -$378.3M | -$372.9M | -$299.7M | -$120.6M | -$198.4M |
| Diluted shares | 447.4M | 274.2M | 207.9M | 175.5M | 125.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $743.3M | $594.4M | $391.6M | $549.9M | $285.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $231.4M |
| Total debt | $18.7M | $27.4M | $1.1M | $633.0K | $10.1M |
| Total assets | $1.47B | $1.45B | $653.7M | $701.3M | $610.3M |
| Total liabilities | $343.3M | $413.8M | $190.3M | $215.5M | $67.4M |
| Shareholders' equity | $1.13B | $1.03B | $463.4M | $485.8M | $542.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology